Mixed Phenotype Acute Leukemia Clinical Trials in Palo Alto, California

4 studies are recruiting for mixed phenotype acute leukemia in Palo Alto, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

    Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, …

    Stage
    Phase 1
    Ages
    0 and older
    Site
    Stanford Cancer Institute, Palo Alto, California
    Locations
    57 in total
    Run by
    Syndax Pharmaceuticals

    See if you can join NCT04065399 on ClinicalTrials.gov

  2. Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of prote…

    Stage
    Phase 3
    Ages
    1 to 25
    Site
    Lucile Packard Children's Hospital Stanford University, Palo Alto, California
    Locations
    231 in total
    Run by
    Children's Oncology Group

    See if you can join NCT03959085 on ClinicalTrials.gov

  3. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

    Stage
    Phase 1
    Ages
    Up to 22
    Site
    Lucile Packard Children's Hospital Stanford University, Palo Alto, California
    Locations
    184 in total
    Run by
    PedAL BCU, LLC

    See if you can join NCT04726241 on ClinicalTrials.gov

  4. Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

    The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.

    Stage
    Phase 1
    Ages
    18 to 70
    Site
    Stanford University, Palo Alto, California
    Run by
    Stanford University

    See if you can join NCT06551584 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.